Linxia Wang Database
Description
Background: Type 2 diabetic patients represent a high risk group with a greater incidence of osteoporosis and fracture as compared with age matched non-diabetic women. Previous studies have suggested that glucagon-like peptide-1 (GLP-1) and its receptor agonists exert beneficial influence on bone. However, little is known the effects of liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), on bone metabolism in type 2 diabetic osteoporosis rats model. The aim of the present study was to investigate the influence of liraglutide on the skeletal system in type 2 diabetic osteoporosis rats. Methods: The experiment was conducted on 2.5-3 month-old female Wistar rats, divided into 6 groups (n = 20 per group): NC - control rats, DM + V - type 2 diabetes control rats, DM + L - type 2 diabetes rats receiving liraglutide ( 0.6 mg/d ) , NOVX - ovariectomized control rats, DOVX + V - diabetic ovariectomized control rats, DOVX + L - diabetic ovariectomized rats receiving liraglutide ( 0.6 mg/d ). We evaluated the skeletal effects of liraglutide on serum bone alkaline phosphatase (B-ALP), bone mineral density (BMD) and bone strength. The effect of liraglutide on the bone marrow mesenchymal stem cells (BMSCs) from the 6 groups rats was also studied. Results: Daily administration of liraglutide significantly increased B-ALP, BMD and bone strength in type 2 diabetic osteoporosis rats in vivo. Moreover, this effect continued to promote osteogenic differentiation, increase GLP-1 receptor (GLP-1R) expression and Akt phosphorylation in BMSCs in vitro. Conclusions: Liraglutide improved bone metabolism in part by targeting Akt through GLP-1R in type 2 diabetic osteoporosis rats. So liraglutide, in the therapy of type 2 diabetic osteoporosis, may have a beneficial effect on bone remodeling.